RHS is a developer of sophisticated novel molecular tools for amplifying DNA and determining the genetic contents of a single cell.
Published clinical studies have shown that a primary reason for IVF failure is the embryo having the wrong number of chromosomes, which is known as aneuploidy. One of the most significant recent advances to improve IVF success rates has been the introduction of advanced Pre-implantation Genetic Screening (PGS), where embryos are screened to determine whether they have the correct number of chromosomes before being selected for IVF transfer.
Specifically developed to offer an integrated, easy to use and interpret, price competitive product, RHS’s EmbryoCellect™ is a Pre-implantation Genetic Screening kit designed to increase the chance of a successful IVF cycle.
RHS recently listed on the Australian Stock Exchange (ASX:RHS). Prior to its listing, the company received over $1 million in grants from both the Australian and South Australian Governments and raised $5.5 million in venture capital investment.
COOE delivers practical and sustainable solutions in environmental science and engineering to industry and governments.Read More
Ziltek provides remediation solutions for environmental consultants, contractors, landowners, industry and government agencies.Read More
Flinders Fertility provides treatment to couples who are not able to conceive on their own.Read More
CPR Pharma Services
CPR Pharma Services (‘CPR’) is a full-service CRO with an international reputation for delivering high quality bioanalytical and clinical trial results.Read More